3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
2
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, AIDS-Related
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Monocytic, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hepatoblastoma
1
Carcinoma, Renal Cell
1
Interventions
Melphalan
4
Irinotecan
4
Filgrastim
4
Cyclophosphamide
4
Busulfan
4
fludarabine
3
Topotecan
3
Temozolomide
3
Granulocyte Colony-Stimulating Factor
3
pegfilgrastim
2
liposomal doxorubicin
2
Thiotepa
2
Sirolimus
2
Peripheral Blood Stem Cell Transplantation
2
Doxorubicin
2
Bone Marrow Transplantation
2
trioctyl phosphine oxide
1
ribociclib
1
regorafenib
1
poly ICLC
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
omburtamab I-131
1
olaparib
1
mocetinostat
1
lexatumumab
1
irinotecan sucrosofate
1
fludarabine phosphate
1
cixutumumab
1
ceritinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Rhabdomyosarcoma
×
pegylated granulocyte colony-stimulating factor
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled